Treatment of LSCD With DM
Limbal Stem-cell Deficiency, Congenital Aniridia
About this trial
This is an interventional treatment trial for Limbal Stem-cell Deficiency focused on measuring congenital aniridia, limbal stem cell deficiency, Descemet's Membrane
Eligibility Criteria
Inclusion Criteria: Arm 1: partial LSCD (involving less than 75% of the limbus, or <75% of the corneal surface) Visually significant (best-corrected visually acuity 20/100 or worse) Arm 2: total/near-total LSCD with recurrent erosions or PEDs (involving more than 75% of the limbus, or more than 75% of the corneal surface) Visually significant (best-corrected visually acuity 20/100 or worse) PLUS Persistent epithelial defects last >2 weeks despite maximal medical therapy OR Recurrent erosions occuring at least once every month Exclusion Criteria: Pregnant women Prisoners (vulnerable population) Adults lacking capacity to consent (vulnerable population) Adults unable to sign consent due to non-english speaking or illiterate (vulnerable population)
Sites / Locations
- University of Minnesota
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Visually significant partial LSCD
Total/near-total LSCD with recurrent or persistent epithelial defects (PED)
Patient with visually significant partial LSCD, as defined by a best corrected visual acuity of 20/100 or less, and partial LSCD on slit lamp exam with at least 25% of the limbus intact or at least 25% of the corneal surface covered with corneal epithelium will be enrolled in the first arm.
Patient with visually significant total LSCD, as defined by a best corrected visual acuity of 20/100 or less, and total LSCD on slit lamp exam with over 25% of the limbus intact or less than 25% of the corneal surface covered with corneal epithelium; and a history of a persistent epithelial defect that has persisted over 2 weeks despite maximal medical therapy, or a history of recurrent epithelial erosions that occur more frequently than once a month; will be enrolled in the second arm.